Prosecution Insights
Last updated: November 04, 2026

Indivior Inc.

Technology area: Biotechnology & Pharmaceuticals

2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready

Analysis

Indivior Inc. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners and 2 distinct art units. This indicates that the company's active patent applications are being evaluated independently by different examiners, with no overlap in the personnel or the specific art units involved. The 2 pending office actions are the only current matters requiring active prosecution responses.

The busiest examiner is SOROUSH, LAYLA, who is managing 1 pending office action. With 2 pending office actions spread across 2 distinct examiners, the prosecution requires a case-specific approach for each matter. The use of 2 distinct art units suggests that the technologies, while both under the Biotechnology & Pharmaceuticals umbrella, are classified into different specialized groups within the patent office. Practitioners should prepare for 2 separate review processes, as the 2 distinct art units may apply different precedents or examination guidelines to the pending cases.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

2
Total Pending OAs
1
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
2
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (50%)
Double-patenting + other1 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

2
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

20 h
Manual time on pending OAs
4 h
Time saved (low, 20%)
7 h
Time saved (mid, 35%)
0.2 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
SOROUSH, LAYLA 1 40.4% +43.6%
CONIGLIO, AUDREA JUNE BUCKLEY 1 53.0% +20.2%

Interview Candidates (2)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.

App #TitleExaminerDue in
18174858 Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose CONIGLIO, AUDREA JUNE BUCKLEY 120d overdue
18753188 COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE SOROUSH, LAYLA —

Top Art Units

Art UnitApps
1622 1
1617 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18753188 COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE SOROUSH, LAYLA 1622 §103DP Non-Final OA — Pending Jun 25, 2024
18174858 Methods, Parenteral Pharmaceutical Formulations, and Devices for the Prevention of Opioid Overdose CONIGLIO, AUDREA JUNE BUCKLEY 1617 §103 Final Rejection 120d overdue Pending Feb 27, 2023

Managing Indivior Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Indivior Inc. have?

Indivior Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.

Which USPTO examiner handles the most Indivior Inc. applications?

Layla Soroush has the most, with 1 of Indivior Inc.'s pending office actions.

What technology area are Indivior Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month